In this MTX+PNL vs TCZ+PNL in GCA study, we saw 5 pts on MTX+PNL get PJP, very surprising. @EBRheum asked what I knew/hoped he’d ask: why did this happen? PJP is v rare in GCA (https://t.co/oPN0dpvG8Q) & with MTX in other diseases. Worth interrogation! #ACR25 ABST0891 @RheumNow https://t.co/rsbScryIFR

• https://www.sciencedirect.com/science/article/abs/pii/S0049017222002050
• https://x.com/drdavidliew/status/1982831653023256722/photo/1

Is MTX worth anything in GCA? METOGiA: MTX 52w vs TCZ 52w for GCA MTX didn’t achieve non-inferiority to TCZ, but: - clearly it does something - continue both >1y: after MTX/TCZ therapy ended, they ended up with same relapse-free survival, cumulative GC #ACR25 ABST0891 @RheumNow https://t.co/WvvkHKIXuQ

• https://x.com/drdavidliew/status/1982829882553082184/photo/1
• https://x.com/drdavidliew/status/1982829882553082184/photo/1
• https://x.com/drdavidliew/status/1982829882553082184/photo/1

Open-label MTX vs. Toci in GCA in METOGiA Wk 78: 37% w/o relapse in MTX arm 46% w/o relapse in Toci arm MTX was NOT non-inferior to Toci Toci superior in 2ndary endpoints Cumulative doses GC not significantly different #ACR25 #ACRBest @RheumNow Abst 0891 https://t.co/lCaP4EdJ9C

• https://x.com/Dr_Brian_MD/status/1982827205349789731/photo/1

Open label noninferiority RCT "METOGiA" in GCA TCZ improved relapse free survival (83% vs 67% MTX) & pred free remission (81% vs 61% MTX) wk 52. Ignore the weird primary endpt at week 78 Everyone also got pred; are we sure MTX works at all? @RheumNow #ACR25 #ACRBest Abstr#0891 https://t.co/i48JBnawB7

• https://x.com/EBRheum/status/1982824859936669713/photo/1
• https://x.com/EBRheum/status/1982824859936669713/photo/1

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/grsgHFQic5

Is tocilizumab equally effective in ischemic vs. non-ischemic GCA? Ischemic = vision, jaw claudication, or CVA Remission at 6 mo higher in non-ischemic group then with equalization at month 12 No major difference in GCs at month 12 @RheumNow #ACR25 #Abst0739 https://t.co/OeYggSQYx8

• https://x.com/Dr_Brian_MD/status/1982559595559342309/photo/1

2 year extension data from SELECT-GCA: Patients in remission who remained on upadacitinib 15mg daily after 1 year had 90% reduced risk of flare compared to those who switched to placebo Higher rates zoster, CK elevation in UPA group #ACR25 @RheumNow #ACRBest https://t.co/jf8Dh2wCBj

• https://x.com/Dr_Brian_MD/status/1982552487518413161/photo/1

#ACR25 Abstr#803 We need more data to justify biologics before conventional immunosuppressant in #SLE. Post-hoc analysis of 5 Phase 3 RCTs = improved efficacy & GC reduction in BEL+No IS vs PBO+IS. Potential selection bias as control group might be doomed to fail @RheumNow https://t.co/kXmrOUbJzj

• https://x.com/Yuz6Yusof/status/1982529968682008679/photo/1
• https://x.com/Yuz6Yusof/status/1982529968682008679/photo/1

Real-world Indian cohort of 290 axSpA patients, generic tofacitinib achieved low/inactive disease in 89% after 25 months. Most adverse events were mild (e.g., transaminitis 14.5%) and manageable. No serious infections or MACE reported. A cost-effective alternative to bDMARDs in https://t.co/JBHfNq7kYt

• https://x.com/synovialjoints/status/1982530167512932518/photo/1

Nice SRMA evaluating HCQ dosing >5mg/kg associated w/3.8x risk of retinopathy... ...but <5mg/kg associated w/1.8x risk of SLE flares Morbidity from one of those is easily avoided by regular screening; morbidity from the other can be devastating @RheumNow #ACR25 Abstr#805 https://t.co/1vJXxXqiRC

• https://x.com/EBRheum/status/1982522869562364407/photo/1

What is #nonadherence in #SLE associated with? 115 Pts w #lupus in Spain Overall medication adherence 58%! 👇Reduced if Male Low education No partner -NS adjusted analysis Unemployed Comorbidities 3 or more drugs/pills -NS adjusted #ACR25 @RheumNow @ACRheum #abst0216 https://t.co/CkG6gpiCw3

• https://x.com/Janetbirdope/status/1982521250959565160/photo/1

CE study BEL vs csDMARDs in TriNetX Mortality ~3-4% for MTX/AZA/MMF vs ~1.5% for BEL, ~50% reduction in adjusted analysis Pretty surprising given mediocre results from BLISS RCTs, but strong research group & lotsa fancy stats Do you believe it? #ACR25 @RheumNow Abstr#0804 https://t.co/Yex98EYDjP

• https://x.com/EBRheum/status/1982518842867015986/photo/1
• https://x.com/EBRheum/status/1982518842867015986/photo/1